BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer

Sambiasi,Domenico; Lambo,Rossana; Pilato,Brunella; Tommasi,Stefania; Trojano,Giuseppe; Kardhashi,Anila; Digennaro,Maria; Trojano,Vito; Simone,Gianni; Paradiso,Angelo

doi:10.3892/or.2013.2802

BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer

Authors:
- Domenico Sambiasi
- Rossana Lambo
- Brunella Pilato
- Stefania Tommasi
- Giuseppe Trojano
- Anila Kardhashi
- Maria Digennaro
- Vito Trojano
- Gianni Simone
- Angelo Paradiso
View Affiliations

Affiliations: National Cancer Research Centre ‘Giovanni Paolo II’, I-70124 Bari, Italy
Published online on: October 22, 2013 https://doi.org/10.3892/or.2013.2802
Pages: 365-369

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The clinical outcome of BRCA mutation carriers and non-carriers still remains a topic of discussion. In order to interpret controversial data, in the present study, we analyzed a large consecutive monoinstitutional series of breast cancer patients and relatives with familial features carrying or not carrying BRCA mutations. The intense research in recent years regarding the clinical genetics of patients with breast or ovarian cancer and their relatives has allowed the organization of a unique database comprising anamnestic, clinical, pathological and molecular data. Families with two or more cases of breast cancer under the age of 50 years, or with three cases at any age, were identified. From June, 2003 to June, 2010, a total of 202 patients (136 probands + 66 relatives) from 45 families were included in the analysis. A total of 136 (49 carrier and 87 non-carrier) cases had a cancer diagnosis at the time of their genetic testing. Twenty and 24 events were observed in the carrier and control group, respectively. The 10-year disease-free suvival rate was 57% for patients in the control group compared with 50% for patients carrying a BRCA mutation (P=0.15 by log-rank test). Finally, 66 (32 genetic and 34 control) cases were unaffected at the time of molecular analysis, and 6 new cases of cancer were observed in the carriers, while no new cases were detected in the control cohort. Thus, at age 50, 40% of carriers had a high risk of disease (P=0.0069 by log-rank test). Our data support the hypothesis that the presence of BRCA mutations does not alter the clinical outcome for hereditary breast cancer patients. Conversely, BRCA mutations are proven to be crucial for prediction of risk in healthy relatives from carrier families.

View Figures

View References

1	Emery J, Lucassen A and Murphy M: Common hereditary cancers and implications for primary care. Lancet. 358:56–63. 2001. View Article : Google Scholar : PubMed/NCBI
2	Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 94:1365–1372. 2002. View Article : Google Scholar : PubMed/NCBI
3	Easton DF, Bishop DT, Ford D and Crockford GP: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 52:678–701. 1993.PubMed/NCBI
4	King MC, Marks JH and Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302:643–646. 2003. View Article : Google Scholar : PubMed/NCBI
5	Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 72:1117–1130. 2003. View Article : Google Scholar
6	Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 91:1310–1316. 1999. View Article : Google Scholar : PubMed/NCBI
7	Liede A, Karlan BY and Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 22:735–742. 2004. View Article : Google Scholar : PubMed/NCBI
8	Metcalfe K, Lubinski J, Lynch HT, et al: Family history of cancer and cancer risk in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst. 102:1874–1878. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lee EH, Park SK, Park B, et al: Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat. 122:11–25. 2010.
10	Adem C, Reynolds C, Soderberg CL, et al: Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer. 97:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
11	Chappuis PO, Nethercot V and Foules WD: Clinico-pathological characteristics of BRCA1 and BRCA2-related breast cancer. Semin Surg Oncol. 18:287–295. 2000. View Article : Google Scholar : PubMed/NCBI
12	Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. The Breast Cancer Linkage Consortium. Lancet. 349:1505–1510. 1997. View Article : Google Scholar : PubMed/NCBI
13	Rennert G, Bisland-Naggan S, Barnett-Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 357:115–123. 2007. View Article : Google Scholar : PubMed/NCBI
14	Budroni M, Cesaraccio R, Coviello V, et al: Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer. 9:622009. View Article : Google Scholar : PubMed/NCBI
15	Verhoog LC, Brekelmans CT, Seynaejjve, et al: Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 83:384–386. 2000. View Article : Google Scholar : PubMed/NCBI
16	Metcalfe K, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 22:2328–2335. 2004. View Article : Google Scholar : PubMed/NCBI
17	Pierce LJ, Levin AM, Rebbeck TR, et al: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 24:2437–2443. 2006.PubMed/NCBI
18	Sariego J: The impact of facility volume/size on breast cancer treatment and outcome. Am Surg. 76:1333–1337. 2010.PubMed/NCBI
19	Paradiso A, Giardina C and Meyer JS: Statewide study of diagnostic agreement in breast pathology. J Natl Cancer Inst. 91:1076–1077. 1999. View Article : Google Scholar : PubMed/NCBI
20	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar
21	Tommasi S, Crapolicchio A, Lacalamita R, et al: BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutat Res. 578:395–405. 2005. View Article : Google Scholar : PubMed/NCBI
22	Tommasi S, Pilato B, Pinto R, et al: Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res. 644:64–70. 2008. View Article : Google Scholar : PubMed/NCBI
23	Mueller CR, Kristoffersson U and Stoppa-Lyonnet D: External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN’s experience of 3 years. Ann Oncol. 15(Suppl 1): i14–i17. 2004.PubMed/NCBI
24	Lawless JS: Statistical Models and Methods for Lifetime Data. John Wiley and Sons; New York, NY: 1982
25	Cox DR: Regression models and life tables. JR Stat Soc. 34:187–220. 1972.
26	Sweet SA: Data Analysis with SPSS. Allyn and Bacon; Boston, MA: 1998
27	Robson M, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6:R8–R17. 2004. View Article : Google Scholar : PubMed/NCBI
28	Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al: Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer. 41:2304–2311. 2005. View Article : Google Scholar : PubMed/NCBI
29	Brekelmans CTM, Tilanus-Linthorst MMA, Seynaeve C, et al: Tumor characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 43:867–876. 2007. View Article : Google Scholar : PubMed/NCBI
30	Delaloge S, Kloos I, Ariane D, et al: Young age is the major predictor of local relapse among conservatively treated BRCA1-, BRCA2-, or non BRCA-linked hereditary breast cancer (BC). Proc Am Soc Clin Oncol. 22:412003.